The goal of the trial is the early detection of cardiotoxicity in patients treated with anthracycline-based chemotherapy. Current diagnostics, such as troponin T, NT-pro-BNP, electrocardiogram, and echocardiography, are not able to identify early myocardial damage. Therefore, this study aims to identify early myocardial damage by using cardiac magnetic resonance imaging.
The primary endpoint of this study is the change in relaxation times in CMR before, during, and after therapy.
Furthermore, the study analyzes:
* other abnormal results in CMR * changes in troponin T and NT-pro-BNP * changes in global longitudinal strain in echocardiography and correlation with results of CMR * detection of new biomarkers in blood, urine, or stool
None
Inability to provide informed consent
Prior administration of an anthracycline
High-dose cyclophosphamide (>1,000 mg/m² or >10 mg/kg)
HER2 inhibitors